Tempus AI Faces Short-Term Weakness Amid Technical Sell-Off and Mixed Fundamental Outlook

Technical Analysis

Tempus AI, Inc. (NASDAQ: TEM) closed at $64.78 on May 14, 2025, down 5.99% from the prior session amid a high intraday range of $71.94 and a low of $64.27. The stock recently broke below near-term resistance at $65.22, signaling potential short-term weakness. Volume at 8.25 million shares fell below the 12.56 million average, indicative of a somewhat subdued sell-off rather than panic. The Relative Strength Index (RSI) sits at 63, reflecting that the stock remains below overbought territory but has lost some momentum. Moving averages reinforce the recent bullish trend: the last closing price remains well above the 50-day ($49.89) and 200-day ($51.17) averages, highlighting strong upward medium-to-long-term momentum. The MACD of 5.65 over three months supports bullish momentum but may warrant caution given the recent pullback. A stop-loss around $61.06 and support at $59.10 offer nearby downside thresholds. The Average True Range (ATR) at $8.77 indicates significant price volatility in recent sessions.

For the next trading day (May 15), the close below resistance and modest volume suggest potential continuation of consolidation or mild selling pressure heading toward support levels near $61-$59. In the upcoming week, given the absence of earnings until August and mixed intraday price action, expect sideways movement within a $59-$66 range as market participants digest recent strategic news and await further catalysts.

Fundamental Analysis

Tempus AI exhibits a market capitalization of approximately $10.69 billion, operating as a leading AI-enabled precision medicine company. Despite positive narrative developments, including a new multi-year collaboration with Boehringer Ingelheim aimed at advancing cancer therapeutics, earnings metrics remain challenging. The company reports a negative trailing twelve months EPS of -$5.16 and an unprofitable price-to-earnings (PE) ratio of -12.32, reflecting ongoing losses during the growth phase. The discounted cash flow (DCF) valuation is deeply negative at -31.20, implying that intrinsic value from a purely cash flow perspective remains below current market price, reinforcing a high-growth, high-burn profile typical of AI and biotech innovators.

Analyst consensus tilts toward a “Hold” with price targets centered near $57.50, beneath the current share price, suggesting limited near-term upside according to prevailing market expectations. The consensus on trading ratings leans toward 5 Holds and 4 Buys, with no Sell assessments, demonstrating measured optimism but a wait-and-see posture. The upcoming Q3 earnings report in August may be a pivotal event to reassess valuation as the firm advances research milestones and monetization of collaborations.

Long-term investment potential is supported by Tempus' expanding technological moat in artificial intelligence-driven clinical trials and precision oncology datasets. The healthcare AI market is forecast to grow significantly, with increasing pharma partnerships, embedding Tempus firmly within a secular growth industry. However, profitability remains distant, and risks related to clinical development timelines and capital requirements persist.

Intrinsic Value and Long-Term Outlook

The current DCF valuation suggests the firm’s negative free cash flows weigh heavily on intrinsic valuation, indicating that current market pricing factors in expectations for future transformative revenue growth rather than near-term earnings. The notable collaboration with Boehringer Ingelheim extends Tempus' foothold in oncology, potentially leading to meaningful long-term value creation. Advanced AI adoption in clinical research and real-world evidence collection places Tempus in a strategic position for cumulative competitive advantage.

While the fundamental growth thesis aligns with AI-driven healthcare innovation, intrinsic value is not realized in the near term based on current cash flows. Investors seeking long-term exposure to cutting-edge AI healthcare solutions may find this stock aligned with speculative growth profiles but should temper expectations for near-term profitability.

Overall Evaluation

Temporarily weakened by profit-taking and proximity to resistance, the stock exhibits strong technical support in the mid-$50s and growing institutional interest through collaboration announcements. The fundamental outlook is mixed: robust secular growth opportunity offset by current negative earnings and cash flow metrics.

The stock classifies as a Hold candidate: the bullish long-term narrative is confirmed by strategic partnerships and a growing addressable market, yet valuation signals a cautious approach given negative earnings, overextended short-term momentum, and a consensus target below current prices. Near-term volatility and limited immediate upside frame the stock as one to monitor closely for improvement in cash metrics or earnings progress before reacceleration.